Edwards Lifesciences has been hit with a $10m penalty to settle a court ruling that determined the company violated antitrust law in its acquisition of JC Medical nearly two years ago.
The life sciences giant acquired the transcatheter aortic valve replacement (TAVR) specialist from Singapore-based Genesis Medtech in August 2024.
A complaint filed by the US Federal Trade Commission (FTC) with the District Court of Columbia revealed that Edwards acquired JC Medical for an upfront payment of $115m, with an additional contemporaneous pledge to invest $25m into Genesis itself.
By viewing these payments as independent, the filing highlighted that Edwards avoided the Hart-Scott-Rodino (HSR) Act payment threshold to trigger HSR review, then set at $119.5m, meaning the company unjustly skirted the antitrust law’s mandatory notification and waiting…



